Kenet, GiliChen, Yeu-ChinLowe, GillianPercy, CharlesTran, Huyenvon Drygalski, AnnetteTrossaert, MarcReding, MarkOldenburg, JohannesMingot-Castellano, Maria EvaPark, Young-ShilPeyvandi, FloraOzelo, Margareth C.Mahlangu, JohnnyQuinn, JenniferHuang, MeiReddy, Divya B.Kim, Benjamin2025-01-072025-01-072021-12-01https://hdl.handle.net/10668/24435Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data are scarce. Here, we report real-world data from a global cohort. Participants were men >= 18 years old with severe HA (FVIII = 18 years old with severe HA (FVIII = 6 months of prospective follow-up. Pre-baseline and on-study, the median (range) ABR values for treated bleeds were 2.00 (0-86.0) and 1.85 (0-37.8), respectively; the median (range) annualised FVIII utilisation rates were 3629.0 (1008.5-13541.7) and 3708.0 (1311.0-14633.4) IU/kg/year, respectively; and the median (range) annualised FVIII infusion rates were 120.0 (52.0-364.0) and 122.4 (38.0-363.8) infusions/year, respectively. The median (range) Haemo-QoL-A Total Score was 76.3 (9.4-100.0) (n = 289), ranging from 85.1 in Australia to 67.7 in South America. Physical Functioning was the most impacted Haemo-QoL-A domain in 4/6 geographic regions. Despite differences among sites, participants reported bleeding requiring treatment and impaired physical functioning. These real-world data illustrate shortcomings associated with FVIII prophylaxis for this global cohort of individuals with severe HA.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/haemophilia Anoninterventional studyFVIII prophylaxisOn-demandAdultsEuroqolAfricaSafetyCareresearch article34945255open access10.3390/jcm102459592077-0383https://www.mdpi.com/2077-0383/10/24/5959/pdf?version=1639826140737808400001